製品名
Anti-p53 (Ab-6) (Pantropic) Mouse mAb (DO-1), liquid, clone DO-1, Calbiochem®
biological source
mouse
antibody form
purified antibody
antibody product type
primary antibodies
clone
DO-1, monoclonal
form
liquid
contains
≤0.1% sodium azide as preservative
species reactivity
feline, human
should not react with
mouse, rat
manufacturer/tradename
Calbiochem®
storage condition
do not freeze
dilution
(Frozen sections (1 µg/mL)
Immunoblotting (0.1-1 µg/mL)
Immunocytochemistry (1-2.5 µg/mL)
Immunoprecipitation (1 µg/mL)
Paraffin sections (1 µg/mL, pepsin, heat or pressure cooker pre-treatment required))
isotype
IgG2a
shipped in
wet ice
storage temp.
2-8°C
target post-translational modification
unmodified
Quality Level
Gene Information
human ... TP53(7157)
Analysis Note
Negative Control
SK-OV-3 cells or normal skin tissue
SK-OV-3 cells or normal skin tissue
Positive Control
A431 cells or breast carcinoma tissue
A431 cells or breast carcinoma tissue
Application

Frozen sections (1 g/ml; see application references)
Immunoblotting (0.1-1 g/ml; see application references)
Immunocytochemistry (1-2.5 g/ml; see application references)
Immunoprecipitation (1 g/ml or use Cat. No. OP43A; see application references)
Paraffin sections (1 g/ml, pepsin, heat or pressure cooker pre-treatment required; see application references)
Disclaimer
Toxicity: Standard Handling (A)
General description
Purified mouse monoclonal antibody generated by immunizing BALB/c mice with the specified immunogen and fusing splenocytes with X63Ag8.653 mouse myeloma cells (see application references). Recognizes the ~53 kDa wild-type and mutant forms of p53.
Recognizes the ~53 kDa wild-type and mutant p53 protein in A431 cells and breast carcinoma tissue.
This Anti-p53 (Ab-6) (Pantropic) Mouse mAb (DO-1) is validated for use in Frozen sections, Immunoblotting, ICC, IP, Paraffin sections for the detection of p53 (Ab-6) (Pantropic).
Immunogen
Epitope: Within amino acids 21-25 of human p53
Human
wild type, recombinant, human p53
Other Notes
El-Deiry, W.S., et al. 1994. Cancer Res.54, 1169.
Greenblatt, M.S., et al. 1994. Cancer Res.54, 4855.
Legros, Y., et al. 1994. Oncogene9, 2071.
Barak, Y., et al. 1993. EMBO J.12, 461.
Kastan, M.B., et al. 1992. Cell71, 587.
Kuerbitz, S.J. 1992. Proc. Natl. Acad. Sci. USA89, 7491.
Lane, D.P. 1992. Nature358, 15.
Vojtesek, B., et al. 1992. J. Immunol. Meth.151, 237.
Kastan, M.B., et al. 1991 Cancer Res.51, 6304.
Greenblatt, M.S., et al. 1994. Cancer Res.54, 4855.
Legros, Y., et al. 1994. Oncogene9, 2071.
Barak, Y., et al. 1993. EMBO J.12, 461.
Kastan, M.B., et al. 1992. Cell71, 587.
Kuerbitz, S.J. 1992. Proc. Natl. Acad. Sci. USA89, 7491.
Lane, D.P. 1992. Nature358, 15.
Vojtesek, B., et al. 1992. J. Immunol. Meth.151, 237.
Kastan, M.B., et al. 1991 Cancer Res.51, 6304.
Recognizes both mutant and wild-type p53 under denaturing and non-denaturing conditions. This antibody reacts weakly with rodent p53; we do not recommend it for rodent samples. For gel shift assay, use Cat. No. OP43L resuspended in 100 μl of buffer. Wild-type p53 has a short half life and is present in low amounts in cells. For immunoprecipitation increasing the amount of sample and labeling with 35S-Met for less than or equal to 1 h will aid in visualizing wild-type p53. Antibody should be titrated for optimal results in individual systems.
Packaging
Please refer to vial label for lot-specific concentration.
Physical form
In 0.05 M sodium phosphate buffer, 0.2% gelatin.
Legal Information
CALBIOCHEM is a registered trademark of Merck KGaA, Darmstadt, Germany
適切な製品が見つかりませんか。
製品選択ツール.をお試しください
保管分類
10 - Combustible liquids
wgk
nwg
flash_point_f
Not applicable
flash_point_c
Not applicable
試験成績書(COA)
製品のロット番号・バッチ番号を入力して、試験成績書(COA) を検索できます。ロット番号・バッチ番号は、製品ラベルに「Lot」または「Batch」に続いて記載されています。
Cheng-Wei Chou et al.
Scientific reports, 9(1), 20403-20403 (2020-01-02)
The p53 gene is an important tumour suppressor gene. Mutant p53 genes account for about half of all lung cancer cases. There is increasing evidence for the anti-tumour effects of statins via inhibition of the mevalonate pathway. We retrospectively investigated
Rebecca A Dagg et al.
Cell reports, 19(12), 2544-2556 (2017-06-22)
Acquisition of replicative immortality is currently regarded as essential for malignant transformation. This is achieved by activating a telomere lengthening mechanism (TLM), either telomerase or alternative lengthening of telomeres, to counter normal telomere attrition. However, a substantial proportion of some
Sadie Rice et al.
Viruses, 12(3) (2020-03-19)
Persistent infection by human papillomaviruses (HPVs), small, double-stranded DNA viruses that infect keratinocytes of the squamous epithelia, can lead to the development of cervical and other cancers. The viral oncoprotein E7 contributes to viral persistence in part by regulating host
Surendra Sharma et al.
Virology, 518, 8-13 (2018-02-11)
Modulation of expression of noncoding RNAs is an important aspect of the oncogenic activities of high-risk human papillomavirus (HPV) E6 and E7 proteins. While HPV E6/E7-mediated alterations of microRNAs (miRNAs) has been studied in detail there are fewer reports on
Yuji Masuda et al.
The Journal of biological chemistry, 294(11), 4177-4187 (2019-01-17)
Ubiquitin-specific protease 7 (USP7) regulates various cellular pathways through its deubiquitination activity. Despite the identification of a growing number of substrates of USP7, the molecular mechanism by which USP7 removes ubiquitin chains from polyubiquitinated substrates remains unexplored. The present study
グローバルトレードアイテム番号
| カタログ番号 | GTIN |
|---|---|
| OP43-100UGCN | 04055977227543 |
| OP43-20UGCN | 04055977227123 |
ライフサイエンス、有機合成、材料科学、クロマトグラフィー、分析など、あらゆる分野の研究に経験のあるメンバーがおります。.
製品に関するお問い合わせはこちら(テクニカルサービス)